adrenergic beta agonists

Summary

Summary: Drugs that selectively bind to and activate beta-adrenergic receptors.

Top Publications

  1. ncbi Therapeutic responses in asthma and COPD. Bronchodilators
    James F Donohue
    Division of Pulmonary Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Chest 126:125S-137S; discussion 159S-161S. 2004
  2. ncbi Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease
    Gordon S Lynch
    Basic and Clinical Myology Laboratory, Department of Physiology, The University of Melbourne, Victoria, Australia
    Physiol Rev 88:729-67. 2008
  3. ncbi Overall asthma control: the relationship between current control and future risk
    Eric D Bateman
    Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    J Allergy Clin Immunol 125:600-8, 608.e1-608.e6. 2010
  4. ncbi Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Peter M A Calverley
    University Hospital Aintree, Liverpool, United Kingdom
    N Engl J Med 356:775-89. 2007
  5. ncbi The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol
    Harold S Nelson
    National Jewish Medical and Research Center, Denver, CO, USA
    Chest 129:15-26. 2006
  6. pmc Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing
    F D Martinez
    Respiratory Sciences Center, The University of Arizona College of Medicine, Tucson, Arizona 85724, USA
    J Clin Invest 100:3184-8. 1997
  7. ncbi Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Chest 129:509-17. 2006
  8. ncbi Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties
    S A Green
    Department of Medicine Pulmonary, University of Cincinnati Medical Center, Ohio 45267 0564
    Biochemistry 33:9414-9. 1994
  9. ncbi Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis
    Shelley R Salpeter
    Santa Clara Valley Medical Center, San Jose, CA, USA
    Chest 125:2309-21. 2004
  10. ncbi Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial
    Peter Calverley
    Department of Medicine, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Lancet 361:449-56. 2003

Detail Information

Publications277 found, 100 shown here

  1. ncbi Therapeutic responses in asthma and COPD. Bronchodilators
    James F Donohue
    Division of Pulmonary Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Chest 126:125S-137S; discussion 159S-161S. 2004
    ..The roles of stereoisomers, leukotriene receptor antagonists, and type 4 phosphodiesterase inhibitors in asthma and COPD remain uncertain at this time...
  2. ncbi Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease
    Gordon S Lynch
    Basic and Clinical Myology Laboratory, Department of Physiology, The University of Melbourne, Victoria, Australia
    Physiol Rev 88:729-67. 2008
    ..Understanding beta-adrenergic signaling in skeletal muscle is important for identifying new therapeutic targets and identifying novel approaches to attenuate the muscle wasting concomitant with many diseases...
  3. ncbi Overall asthma control: the relationship between current control and future risk
    Eric D Bateman
    Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    J Allergy Clin Immunol 125:600-8, 608.e1-608.e6. 2010
    ..Asthma guidelines emphasize both maintaining current control and reducing future risk, but the relationship between these 2 targets is not well understood...
  4. ncbi Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Peter M A Calverley
    University Hospital Aintree, Liverpool, United Kingdom
    N Engl J Med 356:775-89. 2007
    ..Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown...
  5. ncbi The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol
    Harold S Nelson
    National Jewish Medical and Research Center, Denver, CO, USA
    Chest 129:15-26. 2006
    ..To compare the safety of salmeterol xinafoate or placebo added to usual asthma care...
  6. pmc Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing
    F D Martinez
    Respiratory Sciences Center, The University of Arizona College of Medicine, Tucson, Arizona 85724, USA
    J Clin Invest 100:3184-8. 1997
    ..No association was found between the beta2AR-27 polymorphism and response to albuterol. These results may explain some of the variability in response to therapeutic doses of albuterol in children...
  7. ncbi Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Chest 129:509-17. 2006
    ..The combination of short-acting beta(2)-agonists and anticholinergics in the treatment of COPD has been well documented, but data on combination of long-acting agents are lacking...
  8. ncbi Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties
    S A Green
    Department of Medicine Pulmonary, University of Cincinnati Medical Center, Ohio 45267 0564
    Biochemistry 33:9414-9. 1994
    ..abstract truncated at 250 words)..
  9. ncbi Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis
    Shelley R Salpeter
    Santa Clara Valley Medical Center, San Jose, CA, USA
    Chest 125:2309-21. 2004
    ..beta(2)-Agonist use in patients with obstructive airway disease has been associated with an increased risk for myocardial infarction, congestive heart failure, cardiac arrest, and acute cardiac death...
  10. ncbi Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial
    Peter Calverley
    Department of Medicine, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Lancet 361:449-56. 2003
    ..We postulated that a combination of these treatments would be better than each component used alone...
  11. pmc The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors
    Jillian G Baker
    Institute of Cell Signalling, C Floor Medical School, Queen s Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
    Br J Pharmacol 144:317-22. 2005
    ..There is therefore considerable potential for developing more selective beta-antagonists for clinical use and thereby reducing the side-effect profile of beta-blockers...
  12. ncbi Beyond the dogma: novel beta2-adrenoceptor signalling in the airways
    M A Giembycz
    Dept of Pharmacology and Therapeutics, Institute of Infection, Immunity and Inflammation, Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada
    Eur Respir J 27:1286-306. 2006
    ....
  13. ncbi Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome
    D Nuyens
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven, Belgium
    Nat Med 7:1021-7. 2001
    ..These results show the possible risk of sudden heart-rate accelerations. The Scn5a(Delta/+) mouse with its predisposition for pacing-induced arrhythmia might be useful for the development of new treatments for the LQT3 syndrome...
  14. ncbi Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease
    Neil C Barnes
    Department of Respiratory Medicine, London Chest Hospital, London, UK
    Am J Respir Crit Care Med 173:736-43. 2006
    ..No currently available treatment is reported to reduce the exaggerated airway wall inflammation of chronic obstructive pulmonary disease...
  15. ncbi High-altitude pulmonary edema
    Norbert F Voelkel
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    N Engl J Med 346:1606-7. 2002
  16. ncbi In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury
    G D Perkins
    Warwick Medical School, University of Warwick, Coventry, UK
    Thorax 63:215-20. 2008
    ..One possible explanation for the delay in change in extravascular lung water is the time required for salbutamol to stimulate alveolar epithelial repair...
  17. ncbi Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure
    H Senzaki
    Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    FASEB J 15:1718-26. 2001
    ....
  18. ncbi An increase in murine skeletal muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) mRNA in response to exercise is mediated by beta-adrenergic receptor activation
    Shinji Miura
    Nutritional Science Program, National Institute of Health and Nutrition, 1 23 1, Toyama, Shinjuku ku, Tokyo 162 8636, Japan
    Endocrinology 148:3441-8. 2007
    ..These data indicate that up-regulation of PGC-1alpha expression in skeletal muscle by exercise is mediated, at least in part, by beta-ARs activation. Among ARs, beta2-AR may mediate an increase in PGC-1alpha by exercise...
  19. pmc Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo
    D I Ball
    Glaxo Group Research Ltd, Ware, Herts
    Br J Pharmacol 104:665-71. 1991
    ..It also causes persistent bronchodilatation in vivo, in the guinea-pig, when administered by the inhaled route...
  20. ncbi Safety of long-acting beta-agonists in stable COPD: a systematic review
    Gustavo J Rodrigo
    Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Av 8 de octubre 3020, Montevideo 11600, Uruguay
    Chest 133:1079-87. 2008
    ..The purpose of this review was to assess the safety, and secondarily the efficacy of LABAs...
  21. ncbi Clinically relevant concentrations of beta2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury
    Daniel F McAuley
    Cardiovascular Research Institute, University of California, San Francisco, CA, USA
    Crit Care Med 32:1470-6. 2004
    ....
  22. ncbi Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model
    William R Henderson
    Department of Medicine, University of Washington, Seattle, WA 98109, USA
    J Allergy Clin Immunol 116:332-40. 2005
    ..The (R)-enantiomer binds to the beta2-adrenergic receptor with greater affinity than the (S)-enantiomer and is responsible for albuterol's bronchodilating activity. (S)-Albuterol augments bronchospasm and has proinflammatory actions...
  23. ncbi The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD
    Nicola A Hanania
    Baylor College of Medicine, Pulmonary Critical Care, Ben Taub General Hospital, 1504 Taub Loop, Houston, TX 77030, USA
    Chest 124:834-43. 2003
    ....
  24. ncbi Scientific rationale for using a single inhaler for asthma control
    P J Barnes
    Section of Airway Disease, National Heart and Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK
    Eur Respir J 29:587-95. 2007
    ..There is now a strong scientific rationale for single inhaler therapy in asthma, but more research is now needed to better understand the mechanisms involved...
  25. ncbi Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation
    Malcolm Johnson
    GlaxoSmithKline Research and Development, Greenford Road, Middlesex UB6 0HE, United Kingdom
    J Allergy Clin Immunol 117:18-24; quiz 25. 2006
    ..The synergy between the beta(2)-receptor and the glucocorticoid receptor functions has implications for the combined use of beta(2)-agonists and corticosteroids in the treatment of respiratory disease...
  26. ncbi Overview of the effects of beta-adrenergic receptor agonists on animal growth including mechanisms of action
    H J Mersmann
    USDA ARS Children s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    J Anim Sci 76:160-72. 1998
    ..Furthermore, the pharmacodynamic properties of a particular agonist are complex and expected to vary among species as well as within the same species at different ages or when fed different diets...
  27. ncbi Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial
    Shawn D Aaron
    The Ottawa Health Research Institute and University of Ottawa, Ottawa, Ontario, Canada
    Ann Intern Med 146:545-55. 2007
    ..Treatment of moderate or severe chronic obstructive pulmonary disease (COPD) with combinations of inhaled corticosteroids, long-acting beta-agonists, and long-acting anticholinergic bronchodilators is common but unstudied...
  28. pmc Ser-2030, but not Ser-2808, is the major phosphorylation site in cardiac ryanodine receptors responding to protein kinase A activation upon beta-adrenergic stimulation in normal and failing hearts
    Bailong Xiao
    Cardiovascular Research Group, Department of Physiology and Biophysics, University of Calgary, Calgary, Alberta, Canada
    Biochem J 396:7-16. 2006
    ..Our results also suggest that phosphorylation of RyR2 at Ser-2030 may be an important event associated with altered Ca2+ handling and cardiac arrhythmia that is commonly observed in heart failure upon beta-adrenergic stimulation...
  29. ncbi Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD
    M Cazzola
    Department of Respiratory Medicine, A Cardarelli Hospital, Unit of Pneumology and Allergology, Naples, Italy
    Respir Med 97:453-7. 2003
    ..The results indicate that an inhaled combination therapy with a long-acting beta2-agonist and an inhaled corticosteroid appears to be effective in improving airway limitation after acute administration in patients suffering from COPD...
  30. ncbi Alveolar epithelial fluid transport in acute lung injury: new insights
    C Sartori
    Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94143 0130, USA
    Eur Respir J 20:1299-313. 2002
    ..Very recent data suggest that mechanisms that augment transepithelial sodium transport and enhance the clearance of alveolar oedema may lead to more effective prevention or treatment for some types of pulmonary oedema...
  31. ncbi Beta-agonist intrinsic efficacy: measurement and clinical significance
    Nicola A Hanania
    Section of Pulmonary and Critical Care Medicine, Department of Medicine, Baylor College of Medicine and the Houston Veterans Administration Medical Center, Texas 77030, USA
    Am J Respir Crit Care Med 165:1353-8. 2002
  32. ncbi Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters
    H M Schuller
    Experimental Oncology Laboratory, College of Veterinary Medicine, University of Tennessee, Knoxville 37906, USA
    J Cancer Res Clin Oncol 126:624-30. 2000
    ..We have recently shown that the growth of cell lines derived from human PACs is controlled by beta-adrenergic receptors, and that NNK is a high affinity agonist for this receptor family...
  33. ncbi Effects of beta2-agonists on resident and infiltrating inflammatory cells
    Malcolm Johnson
    GlaxoSmithKline, Uxbridge, Middlesex, United Kingdom
    J Allergy Clin Immunol 110:S282-90. 2002
    ....
  34. ncbi A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma
    J C Kips
    Department of Respiratory Diseases, University Hospital Ghent, Ghent, Belgium
    Am J Respir Crit Care Med 161:996-1001. 2000
    ..In conclusion, no significant differences in sputum markers of airway inflammation were observed during a 1-yr treatment with a low dose of inhaled budesonide plus formoterol compared with a higher dose of budesonide...
  35. ncbi The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors
    Minoo D F Askari
    Experimental Oncology Laboratory, Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, 37996, USA
    J Cancer Res Clin Oncol 131:639-48. 2005
    ..The goal of this study was to elucidate the NNK effects on the signal transduction pathways downstream of both beta(1)- and beta(2)-adrenergic receptors in immortalized human pancreatic HPDE6-c7 cells...
  36. ncbi Hypoxia reduces alveolar epithelial sodium and fluid transport in rats: reversal by beta-adrenergic agonist treatment
    M L Vivona
    Department of Physiology, ,
    Am J Respir Cell Mol Biol 25:554-61. 2001
    ..The dramatic increase of ALC with beta(2)-agonist therapy indicates that the decrease of transepithelial Na and fluid transport during hypoxia is rapidly reversible, a finding of major clinical significance...
  37. ncbi Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Respiratory Medicine, Cardarelli Hospital, Naples, Italy
    Drugs 65:1595-610. 2005
    ..Therefore, beta(2)-agonists must always be used with caution in patients with cardiopathies because these agents may precipitate the concomitant cardiac disease...
  38. ncbi Denopamine, a beta(1)-adrenergic agonist, increases alveolar fluid clearance in ex vivo rat and guinea pig lungs
    T Sakuma
    Department of Pulmonary Medicine, Kanazawa Medical University, Uchinade, Ishikawa 920 0293, Japan
    J Appl Physiol (1985) 90:10-6. 2001
    ..In summary, denopamine, a selective beta(1)-adrenergic agonist, stimulates alveolar fluid clearance in both ex vivo rat and guinea pig lungs...
  39. pmc Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases
    Judith C W Mak
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY
    Br J Pharmacol 135:987-96. 2002
    ..In light of data obtained in this study, we propose that both the decrease in AC activity and the increase in GRK activity, which are reversed by dexamethasone, may underlie beta(2)-adrenoceptor desensitization...
  40. ncbi Strain-dependent beta-adrenergic receptor function influences myocardial responses to isoproterenol stimulation in mice
    Michael D Faulx
    Division of Cardiology, Dept of Medicine, Univ Hospitals of Cleveland and Case Western Reserve Univ, MS 5038, 11100 Euclid Ave, Cleveland, OH 44106 5038, USA
    Am J Physiol Heart Circ Physiol 289:H30-6. 2005
    ..Abnormalities in beta-adrenergic regulation may contribute to strain-related differences in the vulnerability to isoproterenol-induced cardiac changes...
  41. ncbi Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct Cis-acting elements
    Michael R Edwards
    Department of Respiratory Medicine, National Heart and Lung Institute and Wright Fleming Institute of Infection and Immunity, Imperial College London, London W2 1PG, United Kingdom
    J Biol Chem 282:15366-75. 2007
    ....
  42. ncbi Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor
    Richard T Hinkle
    Research Division, Procter and Gamble Pharmaceuticals, 8700 Mason Montgomery Road, Mason, Ohio 45040 9317, USA
    Muscle Nerve 25:729-34. 2002
    ..Together these data demonstrate that the beta2-adrenergic receptor is responsible for both the skeletal muscle hypertrophy and anti-atrophy effects of the beta-adrenergic agonist clenbuterol...
  43. ncbi Efficacy of salmeterol xinafoate in the treatment of COPD
    D A Mahler
    Dartmouth Medical School, Lebanon, NH, USA
    Chest 115:957-65. 1999
    ..To examine and compare the efficacy and safety of salmeterol xinafoate, a long-acting inhaled beta2-adrenergic agonist, with inhaled ipratropium bromide and inhaled placebo in patients with COPD...
  44. pmc Bench-to-bedside review: beta2-Agonists and the acute respiratory distress syndrome
    Gavin D Perkins
    Consultant, Intensive Care Unit, Birmingham Heartlands Hospital, Birmingham, UK
    Crit Care 8:25-32. 2004
    ..The present review examines the evidence supporting a role for beta2-agonists as a specific pharmacological intervention in patients with ARDS...
  45. ncbi Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial
    Rudolf A Baumgartner
    Sepracor Inc, Marlborough, Massachusetts 01752, USA
    Clin Ther 29:261-78. 2007
    ....
  46. pmc Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol
    C N A Palmer
    Asthma and Allergy Research Group, Division of Medicine and Therapeutics, Ninewells Hospital, Dundee, UK
    Thorax 61:940-4. 2006
    ..We studied the effect of this polymorphic variation on asthma exacerbations in children and young adults and its relation to long acting beta(2) agonists...
  47. ncbi Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting
    Silvia Busquets
    Cancer Research Group, Departament de Bioquimica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain
    Cancer Res 64:6725-31. 2004
    ....
  48. ncbi Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease
    Donald A Mahler
    Dartmouth Hitchcock Medical Center, Section of Pulmonary and Critical Care Medicine, 1 Medical Center Drive, Lebanon, NH 03756 0001, USA
    Am J Respir Crit Care Med 166:1084-91. 2002
    ..We conclude that FSC improved lung function and reduced the severity of dyspnea compared with individual components and placebo...
  49. pmc Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    J Gen Intern Med 21:1011-9. 2006
    ..Anticholinergics and beta2-agonists have generally been considered equivalent choices for bronchodilation in chronic obstructive pulmonary disease (COPD)...
  50. pmc Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke
    Ruth E MacRedmond
    Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
    Respir Res 8:84. 2007
    ..Modulation of TLR4 in respiratory epithelium may have important implications for airway inflammation and infection in response to inhaled pathogens...
  51. ncbi The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial
    Gavin D Perkins
    Department of Intensive Care Medicine, Birmingham Heartlands Hospital, UK
    Am J Respir Crit Care Med 173:281-7. 2006
    ..Experimental data suggest that manipulation of alveolar fluid clearance with beta-agonists can accelerate the resolution of alveolar edema and improve survival...
  52. ncbi Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
    O Eickelberg
    Department of Research, University Hospital Basel, CH 4031 Basel, Switzerland
    J Biol Chem 274:1005-10. 1999
    ..Ligand-independent activation of GR by beta2-AR agonists may substantially mediate the anti-inflammatory actions of these drugs observed in vitro and in vivo...
  53. ncbi Rapid onset of tolerance to beta-agonist bronchodilation
    Sarah Haney
    Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand
    Respir Med 99:566-71. 2005
    ..This is easily demonstrated if dilation is tested following methacholine challenge. It is not known how quickly tolerance develops or how long it lasts after stopping beta-agonist therapy...
  54. pmc Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism
    D R Taylor
    Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
    Thorax 55:762-7. 2000
    ..Polymorphisms of the beta(2) adrenoceptor influence receptor function in vitro and asthma phenotypes in vivo. However, their importance in determining responses to inhaled beta agonist treatment has not been clearly defined...
  55. ncbi Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease
    Todd A Lee
    Center for Management of Complex Chronic Care, Edward Hines Jr VA Hospital, Hines, Illinois, USA
    Arch Intern Med 169:1403-10. 2009
    ..Our objective was to evaluate the comparative effectiveness of regimens containing tiotropium bromide vs other medication regimens for chronic obstructive pulmonary disease (COPD) in real-world clinical settings...
  56. ncbi Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility
    Eugene R Bleecker
    Wake Forest University Health Sciences, Winston Salem, NC, USA
    Pulm Pharmacol Ther 21:682-8. 2008
    ....
  57. ncbi Strength training and albuterol in facioscapulohumeral muscular dystrophy
    E L van der Kooi
    Neuromuscular Center Nijmegen, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Neurology 63:702-8. 2004
    ..In patients with facioscapulohumeral muscular dystrophy (FSHD) albuterol may exert anabolic effects. The authors evaluated the effect of strength training and albuterol on muscle strength and volume in FSHD...
  58. ncbi Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD
    Jørgen Vestbo
    Department of Respiratory Medicine, Hvidovre University Hospital, Kettegaard Alle 30, Hvidovre DK 2650, Copenhagen, Denmark
    Respir Med 98:1045-50. 2004
    ..In this trial, therapy with the salmeterol/fluticasone combination produced significant improvements compared to placebo on all main endpoints and the magnitude of these improvements was similar for both men and women...
  59. ncbi Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion
    Masanori Ozaki
    Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan
    Circ J 66:851-6. 2002
    ..These results indicate that endogenous NO might act as a negative modulator for the hypertrophic response to beta-adrenergic stimulation...
  60. ncbi The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease
    Donald A Mahler
    Section of Pulmonary and Critical Care Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    J Allergy Clin Immunol 110:S298-303. 2002
    ..These results collectively demonstrate that long-acting inhaled beta(2)-agonists not only relax bronchial smooth muscle but also provide important clinical benefits in symptomatic patients with COPD...
  61. pmc Evidence that the anti-spasmogenic effect of the beta-adrenoceptor agonist, isoprenaline, on guinea-pig trachealis is not mediated by cyclic AMP-dependent protein kinase
    L Spicuzza
    Department of Thoracic Medicine, Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY
    Br J Pharmacol 133:1201-12. 2001
    ....
  62. ncbi Attenuation of lung inflammation by adrenergic agonists in murine acute lung injury
    V K Dhingra
    University of British Columbia Program of Critical Care Medicine and McDonald Research Laboratories, St. Paul's Hospital, Vancouver, Canada
    Anesthesiology 95:947-53. 2001
    ....
  63. ncbi Norepinephrine induces alveolar epithelial apoptosis mediated by alpha-, beta-, and angiotensin receptor activation
    H E Dincer
    Division of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Am J Physiol Lung Cell Mol Physiol 281:L624-30. 2001
    ..These data suggest that NE induces apoptosis of human and rat AECs through a mechanism involving the combination of alpha- and beta-adrenoceptor activation followed by autocrine generation of ANG II...
  64. ncbi Potentiation of beta-adrenoceptor function in bovine tracheal smooth muscle by inhibition of protein kinase C
    Mark Boterman
    Department of Molecular Pharmacology, University Centre for Pharmacy, A Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Eur J Pharmacol 516:85-92. 2005
    ..Since many mediators and neurotransmitters in allergic airway inflammation can activate PKC, this cross talk may be important in the reduced bronchodilator response of patients with severe asthma...
  65. ncbi In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats
    G Shakhar
    Department of Psychology, Tel Aviv University, Israel
    J Immunol 160:3251-8. 1998
    ..This suppression is induced peripherally and can compromise host resistance to NK-sensitive tumors. Homologies to studies in humans and clinical relevance are discussed...
  66. ncbi Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
    W Szafranski
    Dept Lung Diseases, Voivodeship Specialist Hospital, Radom, Poland
    Eur Respir J 21:74-81. 2003
    ..All treatments were well tolerated. These results suggest a role for budesonide/formoterol in the long-term management of moderate-to-severe chronic obstructive pulmonary disease...
  67. ncbi Fenoterol inhibits superoxide anion generation by human polymorphonuclear leukocytes via beta-adrenoceptor-dependent and -independent mechanisms
    Zafar Nazir Mirza
    Department of Pediatrics, Gunma University School of Medicine, Japan
    Ann Allergy Asthma Immunol 88:494-500. 2002
    ..Beta2-adrenoceptor agonists, used widely as bronchodilator in treating bronchial asthma, may have anti-inflammatory activity...
  68. ncbi A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists
    A van Veen
    Department of Pulmonology, Academic Medical Centre, Meibergdreef 9, University of Amsterdam, Amsterdam 1105 AZ, The Netherlands
    Pulm Pharmacol Ther 16:153-61. 2003
    ..In this respect, differences were observed between salmeterol and formoterol that may represent the expression of partial antagonism by salmeterol...
  69. ncbi Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease
    Malcolm Johnson
    GlaxoSmithKline Research and Development, Greenford Road, Middlesex UB6 OHE, UK
    Proc Am Thorac Soc 1:200-6. 2004
    ..Corticosteroid/beta(2)-agonist combined activity may also overcome the reduced sensitivity to inhaled corticosteroids that has been reported in some patients with COPD...
  70. ncbi Measuring asthma control in group studies: do we need airway calibre and rescue beta2-agonist use?
    E F Juniper
    Department of Clinical Epidemiology and Biostatistics, McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
    Respir Med 95:319-23. 2001
    ..Lowering of the summary score by the omission of the FEV1 question means that data from this abbreviated form cannot be combined with or compared to data collected using the full questionnaire...
  71. ncbi Bronchodilator tolerance: the impact of increasing bronchoconstriction
    J M Wraight
    Dept of Medical and Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
    Eur Respir J 21:810-5. 2003
    ..Increasing bronchoconstriction conferred greater susceptibility to the effects of bronchodilator tolerance...
  72. ncbi Dobutamine modulates lipopolysaccharide-induced macrophage inflammatory protein-1alpha and interleukin-8 production in human monocytes
    Chi Yuan Li
    Department of Anesthesiology, Tri Service General Hospital, Taipei, Taiwan, Republic of China
    Anesth Analg 97:210-5, table of contents. 2003
    ..The site of chemokine regulation is at the transcriptional level for MIP-1alpha and might be at the posttranscriptional level for IL-8...
  73. ncbi Protein kinase C potentiates homologous desensitization of the beta2-adrenoceptor in bovine tracheal smooth muscle
    Mark Boterman
    Department of Molecular Pharmacology, University Centre for Pharmacy, A Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Eur J Pharmacol 529:151-6. 2006
    ....
  74. ncbi Phosphorylation of eukaryotic translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-adrenergic cardiac myocyte hypertrophy
    Stefan E Hardt
    Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ 07103 2714, USA
    Circ Res 94:926-35. 2004
    ....
  75. ncbi Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial
    Elliot Israel
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 364:1505-12. 2004
    ..However, the existence of any genotype-dependent difference has not been tested in a prospective clinical trial...
  76. ncbi Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells
    Manminder Kaur
    Department of Cell Biology and Anatomy, Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary T2N 4N1, Canada
    Mol Pharmacol 73:203-14. 2008
    ....
  77. ncbi Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease
    P M Calverley
    Dept of Medicine, Clinical Sciences, University Hospital Aintree, Liverpool, UK
    Eur Respir J 22:912-9. 2003
    ..Budesonide/formoterol in a single inhaler (Symbicort) maintains the benefit of treatment optimisation, stabilising lung function and delaying exacerbations more effectively than either component drug alone or placebo...
  78. ncbi Up-regulation of airway smooth muscle histamine H(1) receptor mRNA, protein, and function by beta(2)-adrenoceptor activation
    J C Mak
    Department of Thoracic Medicine, Imperial College School of Medicine, National Heart and Lung Institute, London, UK
    Mol Pharmacol 57:857-64. 2000
    ..This mechanism may be involved in the adverse responses encountered with the clinical use of short-acting beta(2)-agonists...
  79. ncbi Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down
    Eric D Bateman
    University of Cape Town, South Africa
    J Allergy Clin Immunol 117:563-70. 2006
    ..Asthma control is the goal of treatment, but little data exist to support treatment strategies for stepping down treatment once control has been achieved...
  80. ncbi Effects of prostaglandin E2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells. Relevance to asthma therapy
    N Lazzeri
    Thoracic Medicine and Cardiothoracic Surgery, National Heart and Lung Institute, London; Pharmacology Department, Dagenham Research Centre, Dagenham, Essex; and Unit of Critical Care Medicine, Royal Brompton Hospital, IC School of Medicine, London, UK
    Am J Respir Cell Mol Biol 24:44-48. 2001
    ..Thus, when HASM cells are activated with cytokines they release PGE2, which acts as a "braking mechanism" to limit the coproduction of GM-CSF. Moreover, agents that elevate cAMP also reduce GM-CSF formation by these cells...
  81. ncbi Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase
    Jerald Curran
    Rush University Medical Center, Chicago, IL 60611, USA
    Circ Res 100:391-8. 2007
    ..The results suggest that beta-AR stimulation enhances diastolic SR Ca leak in a manner that is (1) CaMKII dependent, (2) not protein kinase A dependent, and 3) not dependent on bulk [Ca](i)...
  82. ncbi The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine
    W L Chandler
    Department of Laboratory Medicine, University of Washington, Seattle 98195, USA
    Circulation 92:2984-94. 1995
    ..Exercise to exhaustion and infusions of isoproterenol and phenylephrine were used to study interactions between plasminogen activator regulation and the control of regional blood flow in 10 healthy males...
  83. ncbi Contemporary management of chronic obstructive pulmonary disease: scientific review
    Don D Sin
    Division of Pulmonary Medicine, University of Alberta, Edmonton, Canada
    JAMA 290:2301-12. 2003
    ..The care of patients with chronic obstructive pulmonary disease (COPD) has changed radically over the past 2 decades, and novel therapies can not only improve the health status of patients with COPD but also modify its natural course...
  84. ncbi Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling
    Michael Roth
    Department of Pharmacology and the Woolcock Institute of Medical Research, University of Sydney, NSW 2006, Australia
    Lancet 360:1293-9. 2002
    ..Our aim was to elucidate how glucocorticoids and beta2 agonists affect the growth of human bronchial airway smooth muscle cells...
  85. ncbi The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease
    Don D Sin
    Department of Medicine, Respiratory Division, University of British Columbia, Vancouver, Canada
    Am J Respir Crit Care Med 177:1207-14. 2008
    ..Small studies have suggested that inhaled corticosteroids can suppress systemic inflammation in chronic obstructive pulmonary disease (COPD)...
  86. ncbi Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review
    Gustavo J Rodrigo
    Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo 11600, Uruguay
    Chest 136:1029-38. 2009
    ..However, the evidence has been inconclusive. The aim of this review was to assess the safety and efficacy of LABAs/ICSs compared with LABA monotherapy for patients with moderate-to-very severe COPD...
  87. ncbi Altered cardiac collagen and associated changes in diastolic function of infarcted rat hearts
    R Van Kerckhoven
    Department of Pharmacology, Faculty of Medicine and Health Sciences, Erasmus University Rotterdam, Rotterdam, The Netherlands
    Cardiovasc Res 46:316-23. 2000
    ..Chronic effects of methylprednisolone (5 mg/kg/day) and low-dose aspirin (25 mg/kg/day) on cardiac collagen and left ventricular diastolic function were studied in rat hearts, 21 days after MI...
  88. ncbi Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease
    Malcolm Campbell
    University of Glasgow, Glasgow, UK
    Respir Med 99:1511-20. 2005
    ..Both formoterol regimens were well tolerated with no differences in adverse events or electrocardiogram profiles...
  89. ncbi EP2 receptors mediate airway relaxation to substance P, ATP, and PGE2
    C N Fortner
    Department of Molecular and Cellular Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0576, USA
    Am J Physiol Lung Cell Mol Physiol 281:L469-74. 2001
    ..Taken together, this experimental evidence supports the following two conclusions: EP2 receptors are of primary importance in airway relaxation to PGE2 and relaxation to SP or ATP is mediated through PGE2 acting on EP2 receptors...
  90. ncbi Serious asthma exacerbations in asthmatics treated with high-dose formoterol
    Marianne Mann
    Division of Pulmonary and Allergy Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    Chest 124:70-4. 2003
    ....
  91. ncbi Ultrastructural findings for the mitochondrial subpopulation of mice skeletal muscle after adrenergic stimulation by clenbuterol
    Santosh Sundal
    Department of Biosciences, Himachal Pradesh University, Summer Hill, Shimla 171005, India
    J Physiol Sci 57:7-14. 2007
    ..The ultramicroscopic and morphometric results suggest drug-induced defects in contractile and oxidative activities...
  92. ncbi Clenbuterol antagonizes glucocorticoid-induced atrophy and fibre type transformation in mice
    Maria Antonietta Pellegrino
    Department of Experimental Medicine, Human Physiology Unit, University of Pavia, 27100 Pavia, Italy
    Exp Physiol 89:89-100. 2004
    ..Taken together the results suggest that CL might counteract the unwanted effects on skeletal muscles of chronic treatment with glucocorticoids...
  93. ncbi A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway
    A E Carie
    Drug Discovery Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA
    Oncogene 26:3777-88. 2007
    ..Thus, beta2AR stimulation results in significant suppression of malignant transformation in cancers where it blocks the Raf-1/Mek-1/Erk1/2 pathway by a cAMP-dependent activation of PKA but not EPAC...
  94. ncbi Alveolar epithelial fluid transport can be simultaneously upregulated by both KGF and beta-agonist therapy
    Y Wang
    Cardiovascular Research Institute and Departments of Medicine, Anesthesia, and Physiology, University of California, San Francisco 94143 0130, USA
    J Appl Physiol (1985) 87:1852-60. 1999
    ....
  95. ncbi Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells
    C Hoffmann
    Institut fur Pharmakologie und Toxikologie, Universitat Wurzburg, Versbacher Strasse 9, 97078 Wurzburg, Germany
    Naunyn Schmiedebergs Arch Pharmacol 369:151-9. 2004
    ..These specific mixtures of agonism, antagonism, and inverse agonism at different subtypes may have important implications for the therapeutic use of the respective compounds...
  96. ncbi Isoproterenol improves ability of lung to clear edema in rats exposed to hyperoxia
    F J Saldias
    Division of Pulmonary and Critical Care Medicine, Michael Reese Hospital, University of Illinois at Chicago, Chicago, Illinois 60616, USA
    J Appl Physiol (1985) 87:30-5. 1999
    ....
  97. ncbi A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor
    D A Mason
    Departments of Medicine and Pharmacology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
    J Biol Chem 274:12670-4. 1999
    ..The genetic variation of beta1AR at this locus may be the basis of interindividual differences in pathophysiologic characteristics or in the response to therapeutic betaAR agonists and antagonists in cardiovascular and other diseases...
  98. ncbi Excess mortality in patients with asthma on long-acting beta2-agonists
    J Hasford
    Eur Respir J 28:900-2. 2006
  99. ncbi Calcium channel blockers for tocolysis: a review of their role and safety following reports of serious adverse events
    S G Oei
    Maxima Medical Centre, Department of Obstetrics and Gynaecology, University of Technology, Eindhoven, De Run 4600, P O Box 7777, 5500 MB Veldhoven, The Netherlands
    Eur J Obstet Gynecol Reprod Biol 126:137-45. 2006
    ..To truly establish the safety of tocolytics, all serious adverse effects of tocolytics should be reported to a central point and be critically reviewed...
  100. ncbi The role of inflammation and anti-inflammatory medication in asthma
    P J Barnes
    National Heart and Lung Institute, Department of Thoracic Medicine, London, UK
    Respir Med 96:S9-15. 2002
    ..For many people asthma is associated with complex therapy; thus treatment developments that simplify asthma treatment are an mportant step forward n asthma management...
  101. ncbi The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting
    James G Ryall
    Basic and Clinical Myology Laboratory, Department of Physiology, The University of Melbourne, Victoria 3010, Australia
    Pharmacol Ther 120:219-32. 2008
    ....

Research Grants62

  1. Nutritional Regulation of Leptin Production
    Susan K Fried; Fiscal Year: 2010
    ....
  2. Targeting Airway Inflammation from Concentrated Animal Feeding Operation Dust
    Debra Romberger; Fiscal Year: 2013
    ....
  3. ADIPOCYTE PROTEIN SECRETION AND INSULIN ACTION
    Harvey Lodish; Fiscal Year: 2007
    ..Functional studies and knock-out mice will be generated for each of these secreted proteins as warranted. ..
  4. Novel Topical Therapy for Diabetic Retinopathy using Beta-Adrenergic Receptor Ago
    Jena J Steinle; Fiscal Year: 2011
    ..The proposed studies will demonstrate efficacy, safety and potency of compounds 49b to inhibit diabetic retinopathy ..
  5. GASTRIC ACID SECRETION AND BUFFER CONTENT AFTER EATING
    Mark Feldman; Fiscal Year: 1991
    ..Thus, this research will focus primarily on the role of gastric acid, mucosal defense factors (bicarbonate, prostaglandins) and a campylobacter-like bacterium on acid-peptic diseases...
  6. Analysis of a Novel Homeobox gene in CV Development
    Jonathan A Epstein; Fiscal Year: 2012
    ..We hope to determine if HDAC2 and INPP5F represent new targets for the development of specific therapies for heart disease. ..
  7. CALCIUM AND CONTROL OF RENIN SECRETION
    John Fray; Fiscal Year: 1990
    ....
  8. Finding effective treatments for inhaled chlorine-induced injury related pain
    Timothy J Ness; Fiscal Year: 2013
    ..The present studies will examine the effects of this treatment as monotherapy or in combination with a beta adrenergic agonist on measures of pain and inflammation in murine models. ..
  9. NEUROGENIC INFLUENCES ON LUNG FLUID AND SOLUTE EXCHANGE
    Fred Minnear; Fiscal Year: 1990
    ..A key structure - function relationship to be made is to correlate the amplitude and duration of the vascular hypertensive response with the degree of pulmonary pathology...
  10. ION CHANNELS OF UTERINE MUSCLE DURING PREGNANCY
    Nicholas Sperelakis; Fiscal Year: 1992
    ..Finally, studies will also be done on isolated human myometrial tissue, to compare with the results on animal tissue, in order to provide new information for better management of preterm labor in humans...
  11. STIMULUS PROPERTIES OF COCAINE
    JAMES O DONNELL; Fiscal Year: 1990
    ..Moreover, these results may have clinical relevance for the pharmacological treatment of cocaine abuse...
  12. Cyclic GMP Phosphodiesterase in Signaling
    Hsien Yu Wang; Fiscal Year: 2007
    ..These studies are highly relevant to signaling as well as to elucidation of basis for human diseases in which alterations in signaling pathways translate into aberrant biology. ..
  13. Central betal adrenergic receptors and behavior
    Han Ting Zhang; Fiscal Year: 2004
    ..This will lead to the better understanding of pathophysiology and pharmacotherapy of depression. ..
  14. ACTIVATION OF CFTR MUTANTS IN VIVO FOR CF THERAPY
    MITCHELL DRUMM; Fiscal Year: 1999
    ..If beta-adrenergic agonists and class-specific phospho-diesterase inhibitors can significantly increase chloride transport, it is important to carry out studies on mechanism to determine if the process can be further improved. ..
  15. PROTO-ONCOGENES IN CARDIAC TISSUES
    Tibor Barka; Fiscal Year: 1992
    ..Since cardio-vascular disease remain the leading cause of death in the United States, the relevance of the proposed research to health care is obvious...
  16. IONIC CONTROL OF CARDIAC MUSCLE CONTRACTION: EC COUPLING
    Donald Bers; Fiscal Year: 2004
    ..This work will greatly increase fundamental understanding of key cardiac Ca transport systems in the intact cellular environment under physiological conditions. ..
  17. SIGNAL TRANSDUCTION IN PAROTID ACINAR CELLS
    PURUSHOTHAM KARNAM; Fiscal Year: 1993
    ....
  18. GENETIC ANALYSIS OF MYOMETRIAL FUNCTION IN PARTURITION
    Kathleen Bethin; Fiscal Year: 2004
    ..In the future, this system will be used to study factors involved in stimulation of myometrial contraction rather than maintenance of uterine quiescence. ..
  19. DIASTOLIC PROPERTIES OF DEVELOPING MYOCARDIUM
    Kent Thornburg; Fiscal Year: 1993
    ....
  20. PSYCHONEUROIMMUNOLOGY: MODULATION OF T-CELL FUNCTION
    THOMAS ROSZMAN; Fiscal Year: 1993
    ..Finally, the role of cell adherence in the process of T-cell activation will be studied in the context of the stimulation of the BAR...
  21. CORTICOSTEROID EFFECT ON AIRWAY BETA-ADRENERGIC FUNCTION
    Craig Schramm; Fiscal Year: 1993
    ....
  22. PSYCHONEUROIMMUNOLOGY--MODULATION OF T CELL FUNCTION
    THOMAS ROSZMAN; Fiscal Year: 1999
    ..Finally, the role of cell adherence in the process of T-cell activation will be studied in the context of the stimulation of the BAR. ..
  23. IL-1 AND B-ADRENERGIC SYSTEM OF HUMAN AIRWAY EPITHELIUM
    Steven Kelsen; Fiscal Year: 1999
    ..Data generated in this proposal are likely to increase our understanding of the regulation of expression of the major protein components comprising the betaAR-AC and the effects of airway inflammation on the function of this system. ..
  24. SPECIALIZED TRANSPORT PROPERTIES OF ALVEOLAR EPITHELIUM
    Barbara Goodman; Fiscal Year: 1992
    ....
  25. CARDIOVASCULAR CELL GENE TRANSFER OF ADENYLYL CYCLASE
    Paul Insel; Fiscal Year: 2003
    ....
  26. Study of Intrinsic Bladder Activity by Optical Imaging
    Anthony Kanai; Fiscal Year: 2007
    ..To study the neural-chemical control of spontaneous detrusor activity; and III.) To determine the origin of detrusor overactivity in partially obstructed bladders. ..
  27. SKELETAL MUSCLE ADRENERGIC RECEPTOR PATHOPHYSIOLOGY
    Wade Martin; Fiscal Year: 1993
    ..Data analysis will emphasize evaluation of relationships between alpha1 and beta adrenergic receptor characteristics and agonist responsiveness, plasma catecholamine concentrations, skeletal muscle oxidative capacity...
  28. Role of T3 in Reversing Myocardial Stunning in Aging
    James Tse; Fiscal Year: 2001
    ..abstract_text> ..
  29. EFFECTS OF AGE & RIBOFLAVIN ON B-ADRENERGIC ACTIVITIES
    PURABI DUTTA; Fiscal Year: 1990
    ..These studies should provide useful guidelines for effective pharmacological and nutritional management of elderly patients and for delaying and diminishing the age-related changes in body composition...
  30. ADRENERGIC RECEPTORS IN PULMOLARY VASCULAR MUSCLE
    C Gillis; Fiscal Year: 1980
    ....
  31. ETHNIC DIFFERENCES IN AUTONOMIC CARDIOVASCULAR CONTROL
    Alastair Wood; Fiscal Year: 2000
    ..By defining the factors contributing to the altered cardiovascular response in African-Americans, physicians will be better able to tailor therapy to this group and reduce their present excessive burden of cardiovascular disease. ..
  32. Salivary Stem Cell Identification for Tissue Restoration
    Chih ko Yeh; Fiscal Year: 2004
    ..The results of these studies will ultimately lead to revolutionary treatment of salivary gland diseases. ..
  33. MOTOR DENERVATION, MUSCLE ATROPHY, AND INSULIN
    John Lawrence; Fiscal Year: 2000
    ..The experiments in this proposal should lead to a better understanding not only of how skeletal muscle mass is maintained normally, but also of why muscle wasting occurs after denervation. ..
  34. IN VITRO SCREEN FOR A TYPICAL BETA-ADRENERGIC AGONISTS
    Robert White; Fiscal Year: 1990
    ....
  35. ANALYSIS OF PAROTID GLAND 4B-GALACTOSYLTRANSFERASE
    MICHAEL HUMPHREYS BEHER; Fiscal Year: 1993
    ..These experiences would be extremely valuable and could be applied in my future studies of parotid gland growth and development...
  36. MYOCARDIAL BETA-RECEPTOR REGULATION IN CHRONIC HYPOXEMIA
    Daniel Bernstein; Fiscal Year: 1992
    ....
  37. SUDDEN INFANT DEATH SYNDROME
    HAKAN SUNDELL; Fiscal Year: 1991
    ..We propose to gain further knowledge about factors that interrupt apnea. A better understanding of these mechanisms could eventually lead to identification of potential SIDS victims and to the prevention of their demise...
  38. POTASSIUM CHANNELS IN AIRWAY SMOOTH MUSCLE CELLS
    Michael Kotlikoff; Fiscal Year: 2000
    ....
  39. REGULATION OF CARDIAC FUNCTION BY MUSCARINIC
    EUGENE QUIST; Fiscal Year: 1991
    ..In addition, further insights into the physiological role of cholinergic nerve stimulation on various regions of the heart may be provided...
  40. SYMPATHETIC NERVOUS SYSTEM AND IMMUNE RESPONSES
    Ewa Chelmicka Schorr; Fiscal Year: 1992
    ..We believe that an understanding of how the SNS regulates the immune system, and in particular macrophage function, may have an impact on prevention and treatment of immune-mediated diseases...
  41. MEMBRANE AND MYOFILAMENT CONTROL OF CARDIAC DYNAMICS
    BEATA WOLSKA; Fiscal Year: 2000
    ..Their relative contribution to the enhanced relaxation during different states of beta-adrenergic stimulation in physiological and pathological conditions will be assessed. ..
  42. AUTONOMIC RECEPTORS OF THE PULMONARY VASCULATURE
    CARL BUCKNER; Fiscal Year: 1980
    ....
  43. Lactoferrin in Primate and Mouse Models of Asthma
    Atul Varadhachary; Fiscal Year: 2004
    ..Provide evidence supporting future clinical trials in this indication. ..
  44. TARGET IN ASTHMA THERAPY-BETA ADRENERGIC RECEPTOR KINASE
    COLIN GODDARD; Fiscal Year: 1990
    ..We will also establish secondary screens designed to evaluate the specificity and in vivo effectiveness of lead compounds from the primary high throughput screen...
  45. PLC-Ca+ Signaling in the Vascular Smooth Muscle
    Mingyao Liu; Fiscal Year: 2004
    ..Together, we will understand the molecular basis for the modulation of G-protein mediated PLC-Ca2+ signaling in the vascular smooth muscle cells and the regulation of Ca2+ homeostasis in general. ..
  46. CROSS REGULATION OF SIGNALING IN AIRWAY SMOOTH MUSCLE
    Charles Emala; Fiscal Year: 2002
    ....
  47. CARDIAC ELECTROPHYSIOLOGY: EFFECTS OF IONS AND DRUGS
    Ira Cohen; Fiscal Year: 2003
    ....
  48. CHOLINERGIC & ALPHA-ADRENERGIC RESPONSE IN THE PAROTID
    Joseph Larner; Fiscal Year: 1980
    ..In addition to that, preliminary work will be done to identify the site of the cholinergic modulation of the metabolism of phosphatidylinositol and the identification of the biochemical reactions involved...
  49. DRUGS AND DEVELOPMENT OF THE ADRENERGIC NERVOUS SYSTEM
    Theodore Slotkin; Fiscal Year: 2003
    ....
  50. Fetal & Adolescent Nicotine Effects on CNS 5HT Systems
    Theodore Slotkin; Fiscal Year: 2003
    ..abstract_text> ..
  51. MECHANISMS OF CHLORPYRIFOS DEVELOPMENTAL NEUROTOXICITY
    Theodore Slotkin; Fiscal Year: 2004
    ..Molecular mechanisms of developmental neurotoxicity can be determined and linked to eventual alterations in behavioral performance. ..
  52. SCLERODERMA LUNG STUDY
    Donald Tashkin; Fiscal Year: 2003
    ..abstract_text> ..
  53. LUNG HEALTH STUDY--LONG TERM FOLLOW UP
    Donald Tashkin; Fiscal Year: 2002
    ..All ten of the original LHS clinical centers plan to participate in this study. To minimize bias, all surviving participants of the LHS will be invited to participate, giving a potential sample size of 5600. ..
  54. Response to Beta2-Agonists in Acute Severe Asthma
    Nicola Hanania; Fiscal Year: 2008
    ..abstract_text> ..
  55. Distal Lung Inflammation Effect on Asthma Exacerbations
    Donald Tashkin; Fiscal Year: 2008
    ..This study has the potential to clarify the contribution of the "silent zone" to the persistent morbidity encountered with asthma. ..
  56. INFLAMMATION & CORTICOSTEROID RESPONSES IN SEVERE ASTHMA
    KIAN CHUNG; Fiscal Year: 2005
    ..The molecular mechanisms underlying loss of CR will be examined. These studies should lead to more effective therapies for chronic severe asthma. ..
  57. UCSD Hillcrest Flow Cytometer
    Paul Mills; Fiscal Year: 2003
    ..It will also be the centerpiece for an environment of shared ideas and collaboration among investigators who now utilize cytometry for their research. ..
  58. SYMPATHETIC NERVOUS SYSTEM REGULATION OF CELL ADHESION
    Paul J Mills; Fiscal Year: 2010
    ..abstract_text> ..
  59. NNK, Beta-Adrenergic AA Release and Lung Cancer
    HILDEGARD SCHULLER; Fiscal Year: 2005
    ..2. To determine which products of the AA cascade are formed in untreated cells and in response to NNK, which of these products stimulate DNA synthesis, and what downstream effectors are activated by these products. ..
  60. Preclin. model for prevention of NSCLC in former smokers
    HILDEGARD SCHULLER; Fiscal Year: 2006
    ....
  61. Airway muscle tone, RhoA & Cytoskeletal remodeling
    CAROL HIRSHMAN; Fiscal Year: 2007
    ....